Cue Biopharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Somerville, MA
CUE chart
What traders are saying about $CUE
Latest postsCue Biopharma, Inc. news
- Cue Biopharma, Inc. Estimates – NASDAQ:CUE
TradingView ·
- Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
marketbeat.com ·
- Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Yahoo Finance ·
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharmadive.com ·
- Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
investorshub.advfn.com ·
- Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Yahoo Finance ·
- Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
- Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Yahoo Finance ·
- 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Yahoo Finance ·
- Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
Yahoo Finance ·
- Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
Yahoo Finance ·
- Cue Biopharma Announces $50.0 Million Private Placement
Yahoo Finance ·
Cue Biopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M |
| Diluted EPS | $-0.28 | $-0.72 | $-1.11 | $-1.49 |
| Total assets (year end) | $42.2M | $32.2M | $61.5M | $91.3M |
| Cash and equivalents (year end) | $27.1M | $22.5M | $48.5M | $51.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cue Biopharma, Inc.
- Ticker
- CUE (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Somerville, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1645460
- Former names
- Imagen Biopharma, Inc.
Frequently asked questions
What exchange is Cue Biopharma, Inc. listed on?
Cue Biopharma, Inc. trades on the Nasdaq under the ticker symbol CUE.
What industry is Cue Biopharma, Inc. in?
Cue Biopharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc.'s business address on file with the SEC is in Somerville, MA.
When does Cue Biopharma, Inc.'s fiscal year end?
Cue Biopharma, Inc.'s fiscal year ends on December 31.
How much revenue did Cue Biopharma, Inc. report?
Cue Biopharma, Inc. reported $27.5M in revenue for calendar year 2025, according to its SEC filings.